Dr. Kerrigan on Design and Findings of the PROFILE 1001 Trial in ROS1-Mutated NSCLC
Katie Kerrigan, MD, a hematology/oncology fellow at Huntsman Cancer Institute, University of Utah School of Medicine, discusses the design and findings of the ongoing phase I PROFILE 1001 trial with crizotinib (Xalkori) in ROS1-mutated non–small cell lung cancer (NSCLC).
Katie Kerrigan, MD, a hematology/oncology fellow at Huntsman Cancer Institute, University of Utah School of Medicine, discusses the design and findings of the ongoing phase I PROFILE 1001 trial with crizotinib (Xalkori) in ROS1-mutated non—small cell lung cancer (NSCLC).
PROFILE 1001 is the initial phase I study evaluating the use of crizotinib in heavily pretreated patients with ROS1-mutated advanced NSCLC. Notably, patients with brain metastases were included in the trial, says Kerrigan.
Crizotinib was found to be very effective in those with ROS1-mutated disease, leading to a median progression-free survival of 19.3 months and a median overall survival of 51.4 months. In 2016, the FDA approved crizotinib for the treatment of patients with ROS1-positive metastatic NSCLC, which revolutionized the management of this patient population, concludes Kerrigan.
